Hernández-Sánchez, D.; Leyva-Moral, J.M.; Olalla, J.; Negredo, E.; on behalf of the HOLA Study Group.
Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study. Viruses 2025, 17, 993.
https://doi.org/10.3390/v17070993
AMA Style
Hernández-Sánchez D, Leyva-Moral JM, Olalla J, Negredo E, on behalf of the HOLA Study Group.
Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study. Viruses. 2025; 17(7):993.
https://doi.org/10.3390/v17070993
Chicago/Turabian Style
Hernández-Sánchez, Diana, Juan M. Leyva-Moral, Julian Olalla, Eugènia Negredo, and on behalf of the HOLA Study Group.
2025. "Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study" Viruses 17, no. 7: 993.
https://doi.org/10.3390/v17070993
APA Style
Hernández-Sánchez, D., Leyva-Moral, J. M., Olalla, J., Negredo, E., & on behalf of the HOLA Study Group.
(2025). Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study. Viruses, 17(7), 993.
https://doi.org/10.3390/v17070993
